LENZ Therapeutics Inc. (LENZ) is gearing up for a key regulatory catalyst that could prove to be a defining moment for the company.
The company's lead product candidate, LNZ100, proposed for the treatment of presbyopia, is under FDA review, with a decision expected on August 8, 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com